DHC Stock Analysis: Diversified Healthcare Trust | NASDAQ
REIT - Healthcare Facilities | NASDAQ, USA | Market Cap: 2.121m USD | 12M Return: 156.6% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 14.2M
Qual. Beats: 0
Rev. Trend: 94.8%
Qual. Beats: -2
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Diversified Healthcare Trust (DHC) is a real estate investment trust (REIT) that owns and operates a diversified portfolio of healthcare-related properties across the United States. Its holdings span senior living communities, medical office buildings, and life science facilities, leased to roughly 250 tenants. As of March 31, 2026, the company reported a portfolio of approximately 285 properties in 33 states and Washington, D.C., including 23,901 senior living units and roughly 5.6 million square feet of medical office and life science space.
DHC is externally managed by The RMR Group, an alternative asset manager with approximately $37 billion in assets under management and four decades of commercial real estate experience. The trust is headquartered in Newton, Massachusetts, and was incorporated in Maryland in 1998. As a REIT, DHC is generally required to distribute the majority of its taxable income to shareholders in the form of dividends, a structural feature common to publicly traded real estate companies in the healthcare property sector.
- Senior housing occupancy gains boost NOI growth
- Medical office lease escalations lift rental income
- High leverage and refinancing costs pressure FFO
| Net Income: -320.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.00 > 0.02 and ΔFCF/TA -1.80 > 1.0 |
| NWC/Revenue: 7.95% < 20% (prev 28.41%; Δ -20.46% < -1%) |
| CFO/TA -0.00 > 3% & CFO -8.03m > Net Income -320.2m |
| Net Debt (2.42b) to EBITDA (163.1m): 14.86 < 3 |
| Current Ratio: 113.2 > 1.5 & < 3 |
| Outstanding Shares: last quarter (240.7m) vs 12m ago 0.31% < -2% |
| Gross Margin: 2.11% > 18% (prev 17.59%; Δ -15.47% > 0.5%) |
| Asset Turnover: 32.76% > 50% (prev 30.26%; Δ 2.51% > 0%) |
| Interest Coverage Ratio: -0.40 > 6 (EBIT TTM -93.4m / Interest Expense TTM 232.6m) |
| A: 0.03 (Total Current Assets 121.8m - Total Current Liabilities 1.08m) / Total Assets 4.27b |
| B: -0.70 (Retained Earnings -3.01b / Total Assets 4.27b) |
| C: -0.02 (EBIT TTM -93.4m / Avg Total Assets 4.63b) |
| D: 0.61 (Book Value of Equity 1.62b / Total Liabilities 2.65b) |
| Altman-Z'' = -1.60 = D |
As of July 18, 2026, the stock is trading at USD 9.16 with a total of 1,335,771 shares traded. Over the past week, the price has changed by +4.57%, over one month by +6.64%, over three months by +24.12% and over the past year by +156.58%.
Current recommended Stop Loss: 8.60 (which is 6.1% or 1.8 ATR below the current price).
Diversified Healthcare Trust has received a consensus analysts rating of 3.33. Therefore, it is recommended to hold DHC.
- StrongBuy: 1
- Buy: 0
- Hold: 1
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 9.9 | 7.9% |
P/E Forward = 16.6389
P/S = 1.3976
P/B = 1.3088
P/EG = 1.8917
Revenue TTM = 1.52b USD
EBIT TTM = -93.4m USD
EBITDA TTM = 163.1m USD
Long Term Debt = 2.40b USD (from longTermDebt, last quarter)
Short Term Debt = 1.08m USD (from shortTermDebt, last quarter)
Debt = 2.55b USD (from shortLongTermDebtTotal, last quarter) + Leases 127.8m
Net Debt = 2.42b USD (calculated: Debt 2.55b - CCE 121.8m)
Enterprise Value = 4.54b USD (2.12b + Debt 2.55b - CCE 121.8m)
Interest Coverage Ratio = -0.40 (Ebit TTM -93.4m / Interest Expense TTM 232.6m)
EV/FCF = -565.7x (Enterprise Value 4.54b / FCF TTM -8.03m)
FCF Yield = -0.18% (FCF TTM -8.03m / Enterprise Value 4.54b)
FCF Margin = -0.53% (FCF TTM -8.03m / Revenue TTM 1.52b)
Net Margin = -21.10% (Net Income TTM -320.2m / Revenue TTM 1.52b)
Gross Margin = 2.11% ((Revenue TTM 1.52b - Cost of Revenue TTM 1.49b) / Revenue TTM)
Gross Margin QoQ = -13.62% (prev -13.57%)
Tobins Q-Ratio = 1.06 (Enterprise Value 4.54b / Total Assets 4.27b)
Interest Expense / Debt = 9.14% (Interest Expense 232.6m / Debt 2.55b)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -73.8m (EBIT -93.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 113.2 (out of range, set to none) (Total Current Assets 121.8m / Total Current Liabilities 1.08m)
Debt / Equity = 1.57 (Debt 2.55b / totalStockholderEquity, last quarter 1.62b)
Debt / EBITDA = 14.86 (Net Debt 2.42b / EBITDA 163.1m)
Debt / FCF = -301.7 (out of range, set to none) (Net Debt 2.42b / FCF TTM -8.03m)
Total Stockholder Equity = 1.71b (last 4 quarters mean from totalStockholderEquity)
RoA = -6.91% (Net Income -320.2m / Total Assets 4.27b)
RoE = -18.75% (Net Income TTM -320.2m / Total Stockholder Equity 1.71b)
RoCE = -2.27% (EBIT -93.4m / Capital Employed (Equity 1.71b + L.T.Debt 2.40b))
RoIC = -1.76% (negative operating profit) (NOPAT -73.8m / Invested Capital 4.19b)
WACC = 7.49% (E(2.12b)/V(4.67b) * Re(7.81%) + D(2.55b)/V(4.67b) * Rd(9.14%) * (1-Tc(0.21)))
Discount Rate = 7.81% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 97.99 | Cagr: 0.28%
[DCF] Fair Price = unknown (Cash Flow -8.03m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.39 | # QB: 0
Revenue Correlation: 94.80 | Revenue CAGR: 4.62% | SUE: -1.92 | # QB: -2
EPS current Quarter (2026-06-30): EPS=-0.15 | Chg30d=+3.13% | Revisions=+25% | Analysts=2
EPS next Quarter (2026-09-30): EPS=-0.15 | Chg30d=+6.25% | Revisions=+25% | Analysts=2
EPS current Year (2026-12-31): EPS=-0.60 | Chg30d=-2.27% | Revisions=+0% | GrowthEPS=+49.6% | GrowthRev=-2.3%
EPS next Year (2027-12-31): EPS=-0.47 | Chg30d=-2.15% | Revisions=+0% | GrowthEPS=+19.1% | GrowthRev=+6.9%
[Analyst] Revisions Ratio: +22% (up=4, down=2)